Scarica l'app Stockscreener
82.65
0.08%
-0.07
Dopo l'orario di chiusura:
82.16
-0.49
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$82.72
Aprire:
$82.96
Volume 24 ore:
2.17M
Relative Volume:
0.94
Capitalizzazione di mercato:
$15.99B
Reddito:
$8.41B
Utile/perdita netta:
$760.80M
Rapporto P/E:
21.46
EPS:
3.8513
Flusso di cassa netto:
$1.05B
1 W Prestazione:
-0.86%
1M Prestazione:
-14.37%
6M Prestazione:
-8.07%
1 anno Prestazione:
-13.30%
Intervallo 1D:
$82.05
$83.47
Intervallo di 1 settimana:
$79.12
$85.20
Portata 52W:
$79.12
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Nome
Zimmer Biomet Holdings Inc
Settore
Industria
Telefono
(574) 267-6131
Indirizzo
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
82.65 | 16.00B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
84.90 | 146.02B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.51 | 115.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.97 | 97.84B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.55 | 78.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.34 | 46.86B | 6.30B | 1.07B | 1.09B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-02-20 | Iniziato | William Blair | Mkt Perform |
| 2026-01-09 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Aggiornamento | Roth Capital | Neutral → Buy |
| 2024-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Iniziato | Wolfe Research | Peer Perform |
| 2024-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-21 | Aggiornamento | Argus | Hold → Buy |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Iniziato | ROTH MKM | Neutral |
| 2023-08-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-05-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-03-29 | Iniziato | UBS | Sell |
| 2023-03-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Underweight |
| 2022-10-12 | Iniziato | Jefferies | Underperform |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-04-01 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Underperform |
| 2022-03-02 | Downgrade | Loop Capital | Buy → Hold |
| 2022-02-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Reiterato | Citigroup | Buy |
| 2022-02-08 | Reiterato | Deutsche Bank | Hold |
| 2022-02-08 | Reiterato | JMP Securities | Mkt Outperform |
| 2022-02-08 | Reiterato | JP Morgan | Neutral |
| 2022-02-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Reiterato | Stifel | Buy |
| 2022-02-08 | Reiterato | Truist | Buy |
| 2022-02-08 | Reiterato | UBS | Neutral |
| 2022-02-08 | Reiterato | Wells Fargo | Underweight |
| 2022-02-02 | Downgrade | UBS | Buy → Neutral |
| 2022-01-19 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Downgrade | Needham | Strong Buy → Buy |
| 2021-12-07 | Iniziato | Loop Capital | Buy |
| 2021-11-23 | Downgrade | Argus | Buy → Hold |
| 2021-09-14 | Ripresa | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-09 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Reiterato | Needham | Strong Buy |
| 2020-10-20 | Iniziato | Northland Capital | Market Perform |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-08-05 | Reiterato | Needham | Strong Buy |
| 2020-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Reiterato | Needham | Strong Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-09-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Aggiornamento | Argus | Hold → Buy |
| 2019-07-30 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Aggiornamento | Needham | Buy → Strong Buy |
Mostra tutto
Zimmer Biomet Holdings Inc Borsa (ZBH) Ultime notizie
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MSN
Zimmer Biomet stock (US98956P1021): Leading medical device maker with strong US market presence - AD HOC NEWS
Pacer Advisors Inc. Has $62.74 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet stock (US98956P1021): Leading medical device maker for orthopedics - AD HOC NEWS
Zimmer Biomet raises share repurchase target to up to $1B by year-end - MSN
Zimmer Biomet Holdings | 10-K: FY2025 Annual Report - Moomoo
Fidelity records proposed sale of ZBH common shares (ZBH) - Stock Titan
Zimmer Biomet Holdings (ZBH) Increases Share Repurchase Plan by $250M - GuruFocus
Zimmer Biomet Raises 2026 Share Repurchase Plan to $1 Billion Under Existing Authorization - Minichart
Zimmer Biomet stock (US98956P1021): Leader in orthopedic devices - AD HOC NEWS
Zimmer Biomet Expands 2026 Share Repurchase Program - TipRanks
Zimmer Biomet Raises Fiscal 2026 Share Repurchase Target to $1 Billion - marketscreener.com
Zimmer Biomet Increases Share Repurchase Expectations — Up to $1 Billion by Year End - The Malaysian Reserve
Zimmer Biomet increases 2026 buyback plan to $1 billion By Investing.com - Investing.com South Africa
Zimmer Biomet increases 2026 buyback plan to $1 billion - Investing.com
Zimmer Biomet increases share repurchase expectations -- up to $1 billion by year end - marketscreener.com
KLCM Advisors Inc. Buys 58,427 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet (NYSE: ZBH) lifts 2026 share repurchase expectations to $1B - Stock Titan
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End - PR Newswire
Zimmer Biomet stock hits 52-week low at $79.83 By Investing.com - Investing.com South Africa
A Look at Zimmer Biomet Holdings Inc (ZBH) After 3.3% Decline -- GF Value $126.46 vs Price $79.58 - GuruFocus
Zimmer Biomet (NYSE:ZBH) Reaches New 12-Month LowHere's Why - MarketBeat
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zimmer Biomet stock hits 52-week low at $79.83 - Investing.com
Investors Can Find Comfort In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings Quality - Yahoo Finance
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating a 19.67% Potential Upside in the Medical Device Sector - DirectorsTalk Interviews
Reaffirmed Guidance and CFO Exit Might Change The Case For Investing In Zimmer Biomet (ZBH) - Sahm
Zimmer Biomet falls after CEO exit, unchanged growth outlook - MSN
Zimmer Biomet Earnings: Decent Quarterly Results Aren't Enough to Assuage Investor Worries - Morningstar
Bryn Mawr Trust Advisors LLC Sells 25,448 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
A Look At Zimmer Biomet (ZBH) Valuation After Strong Q1 2026 Results And CFO Transition - simplywall.st
Sequoia Financial Advisors LLC Sells 16,194 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet stock (US98956P1021): Orthopedic device maker reports Q1 results and raises full-year - AD HOC NEWS
Zimmer Biomet (NYSE:ZBH) Rating Increased to Buy at Wall Street Zen - MarketBeat
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Oak Family Advisors LLC Sells 37,733 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
EQUITY INVESTMENT CORP's Zimmer Biomet Holdings Inc(ZBH) Holding History - GuruFocus
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference – Company Announcement - Financial Times
Zimmer Biomet (ZBH) CAO awarded 9,232 RSUs vesting over three years - Stock Titan
How Zimmer Biomet Holdings Inc. (ZBH) Affects Rotational Strategy Timing - Stock Traders Daily
Why Zimmer Biomet (ZBH) is a Top Growth Stock for the Long-Term - Yahoo Finance
Zimmer Biomet (ZBH) Is Down 9.2% After Strong Q1, CFO Exit And Ongoing Buybacks – Has The Bull Case Changed? - Sahm
Robertson Stephens Wealth Management LLC Buys Shares of 12,539 Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating A Potential 18.85% Upside - DirectorsTalk Interviews
Zimmer Biomet Announces Chief Financial Officer Transition - Building Indiana Business
BofA Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $100 - Moomoo
Zimmer Biomet Holdings 1Q 2026: Revenue $2.09B, EPS $1.22— 10-Q Summary - TradingView
Zimmer Biomet (NYSE: ZBH) posts Q1 2026 growth and updates 2026 view - Stock Titan
Zimmer Biomet Ordered to Defend Fraud Claim in Device Deal Case - Bloomberg Law News
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results - Quantisnow
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock - Yahoo Finance
Zimmer Biomet Holdings Inc Azioni (ZBH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.31%
1.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):